Ruxolitinib Cream Demonstrates Long-Term Disease Control in Atopic Dermatitis

As-needed treatment with 1.5% ruxolitinib cream provided sustained disease control in patients with mild to moderate atopic dermatitis (AD), according to findings from the TRuE-AD1 and TRuE-AD2 studies. Among patients who continued treatment for 52 weeks (n=428), rates of clear or almost clear skin improved from 67.1% at week 8 to 77.8% at week 52. Additionally, no days of itch were reported by 36.2% of patients at week 52, compared to 32.7% at week 8. Sleep disturbance-free nights increased from 71.8% to 74.5%, and the proportion of patients with no AD-related quality of life (QoL) burden rose from 57.1% to 59.8%. By the study’s end, 30.0% of participants met all 4 disease control criteria.

The findings, released by Incyte, were presented at the 2025 American Academy of Dermatology Meeting, being held March 7-11, in Orlando, FL.

The randomized controlled trials included patients aged 12 years and older with AD for at least 2 years, an Investigator’s Global Assessment (IGA) score of 2 or 3, and 3%–20% affected body surface area. Participants initially received twice-daily 0.75% or 1.5% ruxolitinib cream or vehicle for 8 weeks, followed by 44 weeks of as-needed treatment with ruxolitinib cream in a long-term safety evaluation period. Disease control assessments incorporated IGA scores, the Patient-Oriented Eczema Measure for itch and sleep disturbance, and the Dermatology Life Quality Index or children’s DLQI.

These findings underscore the efficacy of 1.5% ruxolitinib cream in achieving and maintaining symptom relief and skin clearance while improving QoL in adolescents and adults with mild to moderate AD.

Please click here for the rest of Patient Care news from AAD 2025.

Source: Kircik L, Blauvelt A, Szepietowski C, et al. Ruxolitinib Cream Demonstrated Long-Term Disease Control and Quality of Life Benefits in Adults and Adolescents With Mild to Moderate Atopic Dermatitis. Abstract presented at the 2025 American Academy of Dermatology Meeting; March 7-11, 2025. Orlando, FL.